Sense announces expansion to support lunch of rapid, Point-of-Care molecular diagnostic 

Global molecular diagnostics innovator, Sense Biodetection (Sense), today announced a large-scale investment in the expansion of its manufacturing capacity to support anticipated demand for the Veros™ instrument-free, single-use, rapid point of care molecular device. The investment includes a new Cambridge, England Manufacturing and Development site that is more than six times the size of its current facility, and significant investment in its U.S. manufacturing sites to deliver important automation benefits and enhance production versatility.

The announcement of the new Cambridge facility follows the recent opening of Sense’s new R&D center in Oxford. The new 26,000 sq. ft. Cambridge facility will feature class A office and lab space, accompanied by dedicated class 8 clean rooms for scaled manufacturing.

“Following our recent clinical trials, one of our top priorities has been expanding our facilities to bolster innovation and manufacturing capacity to meet anticipated demand. These investments position us well to meet healthcare’s unmet needs for rapid, instrument free, high-quality molecular diagnostics for a variety of conditions. In addition, it positions us to address the emerging capacity guidelines from government agencies like the FDA for high volume production of COVID-19 tests” said Timothy I. Still, CEO.

Veros™ has the potential to be the first and only instrument-free, single-use, rapid, point-of-care molecular diagnostic testing platform that produces lab-quality results within 15 minutes. Unconstrained by an instrument or reader, the Veros platform has the potential to improve access to rapid, highly accurate, point of care testing for many more people, and help reduce the spread of COVID-19 with faster, more precise diagnoses. Using a proprietary, rapid molecular amplification technology, Veros aims to deliver instrument-free, PCR-quality laboratory results directly to users within minutes.